https://doi.org/10.55788/da5fce71
Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Emerging intralesional therapies for BCC Next Article
Vitiligo and the risk for skin cancer »
« Emerging intralesional therapies for BCC Next Article
Vitiligo and the risk for skin cancer »
Table of Contents: DDD 2025
Featured articles
How to deal with misinformation in the medical world
Paediatric Dermatology
Management of atopic dermatitis in children in 2025
New horizon for classifying and managing vascular anomalies
What’s New?
Novel markers to monitor treatment response and progression in Sézary syndrome
Vitiligo and the risk for skin cancer
Crucial role of TFAP2a in skin health unravelled
Updates in Dermato-oncology
Emerging intralesional therapies for BCC
Diagnosis and management of atypical melanocytic lesions
Expanding treatment armamentarium for actinic keratosis and Bowen’s disease
Social Media and Dermatology
Guiding patients through the social media maze
How to deal with misinformation in the medical world
Auto-inflammatory Diseases
A guide to recognise and manage Schnitzler syndrome in clinical practice
VEXAS syndrome and its cutaneous manifestations
Related Articles
February 3, 2022
Secukinumab also tolerable in paediatric psoriasis patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
